REQUEST A DEMO
Total
USD $0.00
Search more companies

Withus Pharmaceutical. Co.,Ltd. (South Korea)

Main Activities: Pharmaceutical Preparation Manufacturing
Full name: Withus Pharmaceutical. Co.,Ltd. Profile Updated: October 29, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2023 Available in: English Download a sample report

The company is Korea-based company mainly engaged in the production and sale of pharmaceuticals. The Company s main products include circulatory agents, musculoskeletal agents, digestive agents, antibiotics and other prescription drugs. And the Company is engaged in contract manufacturing operation(CMO). The Company was established on August 19, 2004. The Company share was listed on the Korea Securities Dealers Automated Quotation System ( KOSDAQ ) on July 3, 2020.

Headquarters
3/4/5F, Withus Bldg., 9, Dongsan-Ro 12-G
Seoul; Seoul;

Contact Details: Purchase the Withus Pharmaceutical. Co.,Ltd. report to view the information.

Website: http://withuspharm.com

Basic Information
Total Employees:
Purchase the Withus Pharmaceutical. Co.,Ltd. report to view the information.
Outstanding Shares:
Purchase the Withus Pharmaceutical. Co.,Ltd. report to view the information.
Registered Capital:
Purchase the Withus Pharmaceutical. Co.,Ltd. report to view the information.
Financial Auditors:
Purchase the Withus Pharmaceutical. Co.,Ltd. report to view the information.
Incorporation Date:
2004
Key Executives
Purchase this report to view the information.
Chief Executive Officer
Subsidiaries
위더스제약 주식회사
Company Performance
Financial values in the chart are available after Withus Pharmaceutical. Co.,Ltd. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency KRW. Absolute financial data is included in the purchased report.
Net sales revenue
23.87%
Total operating revenue
23.79%
Operating profit (EBIT)
68.45%
EBITDA
56.59%
Net Profit (Loss) for the Period
221.04%
Total assets
9.54%
Total equity
8.72%
Operating Profit Margin (ROS)
2.47%
Net Profit Margin
6.1%
Return on Equity (ROE)
5.83%
Debt to Equity Ratio
-3.7%
Quick Ratio
-0.61%
Cash Ratio
-0.06%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?